Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 21, 2017. The document serves as a report of foreign issuer pursuant to Rule 13a-16 of the Securities Exchange Act of 1934. The primary purpose of this filing is to announce provisional dividend dates for the fourth quarter of 2017 and the first three quarters of 2018.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly an administrative announcement regarding dividend scheduling and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document notes a procedural change regarding the standard settlement cycle for securities transactions, which shifted from T+3 to T+2 effective September 5, 2017. Consequently, the ex-dividend date for ADR holders and ordinary shareholders is now the same date.
Guidance, Outlook, and Dividend Schedule
Management has provided a schedule of indicative dates for dividend payments. These dates are subject to change. The announced schedule is as follows:
- Q4 2017: Results announcement on February 7, 2018; Ex-dividend date on February 22, 2018; Payment date on April 12, 2018.
- Q1 2018: Results announcement on April 25, 2018; Ex-dividend date on May 10, 2018; Payment date on July 12, 2018.
- Q2 2018: Results announcement on July 25, 2018; Ex-dividend date on August 9, 2018; Payment date on October 11, 2018.
- Q3 2018: Results announcement on October 31, 2018; Ex-dividend date on November 15, 2018; Payment date on January 10, 2019.
The filing contains no specific guidance on future earnings, risks, contingencies, or unusual items beyond the standard disclaimer that dates are indicative.
Investor Verification Checklist
- Verify the final dividend amounts and exact payment dates in the official Q4 2017 results announcement scheduled for February 7, 2018.
- Confirm the impact of the T+2 settlement cycle on specific trading strategies for ADR holders versus ordinary shareholders.
- Monitor subsequent filings for any updates to the indicative dates provided in this Form 6-K.